

## Company Fact Sheet

### Headquarters:

25841 Industrial Blvd. Suite 275  
Hayward, CA 94545  
USA  
+1 650.239.9070

### Number of Employees:

268

### RefleXion Medical:

A privately held biotargeting oncology company founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri to create a new radiation treatment modality through biological guidance for the treatment of localized and metastatic cancer.

### RefleXion Technology:

RefleXion is developing a biology-guided radiotherapy (BgRT)\* machine that is the first to utilize the cancer's biology itself to guide radiation delivery, even in tumors that are moving. The technology uses positron emission tomography (PET) to guide personalized radiotherapy. RefleXion's platform enables a leap forward in the ongoing goal of conventional radiotherapy to manage motion, and potentially diminish radiation toxicity, making it feasible to one day treat multiple tumors in parallel during the same session.

Currently, the RefleXion machine is cleared by the U.S. Food and Drug Administration (FDA) for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).

### PET and Radiotherapy:

RefleXion's technology combines PET imaging with stereotactic radiotherapy for localization and real-time tracking at the time of treatment delivery. By using the tumor's own emissions to guide radiation delivery, treatment margins and the radiation dose to healthy tissue may be significantly reduced. This approach represents a significant advance for patients by leveraging a proven modality for visualizing cancer with one of the most effective ways to treat cancer.

### Funding & Investors:

RefleXion has raised \$430M in debt and equity funding. The company is backed by premier investment firms PSP Investments, Ally Bridge Group, TPG Growth/The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, Pfizer Ventures, Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, and Johnson & Johnson Innovation – JJDC, Inc. The company also received grant funding from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program.

**Media Resources:**

Todd Powell, president, CEO  
Sam Mazin, Ph.D., founder, CTO  
Martyn Webster, CFO  
Sean Shirvani, M.D., CMO  
Judy Bartlett-Roberto, vp, marketing

**Media Contact:**

Amy Cook  
[acook@reflexion.com](mailto:acook@reflexion.com)

**Investor Contact:**

Martyn Webster  
[martyn@reflexion.com](mailto:martyn@reflexion.com)

The RefleXion® X1 is cleared for SBRT/SRS/IMRT. BgRT is pending regulatory review and is not commercially available.

735-00047 Rev B